Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin mesylate + pegvorhyaluronidase alfa
- Development stage
- Discontinued
- Lead developer
- Eisai
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of eribulin mesylate, a microtubule inhibitor approved for metastatic breast cancer, and pegvorhyaluronidase alfa, an enzyme that degrades hyaluronan in the tumor microenvironment. This combination was investigated for the treatment of HER2-negative, high-hyaluronan (HA) metastatic breast cancer.
- Brand names
- HALAVEN
- Other names
- pegvorhyaluronidase alpha
02
Targets
Microtubule
Beyond the preview
Go deeper on eribulin mesylate + pegvorhyaluronidase alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin mesylate + pegvorhyaluronidase alfa.